[ACAD] ACADIA Pharmaceuticals Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 29.75 Change: 2.08 (7.52%)
Ext. hours: 29.65 Change: -0.1 (-0.34%)

chart ACAD

Refresh chart

Strongest Trends Summary For ACAD

ACAD is in the long-term up 1174% in 15 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by Pimavanserin that is in the Phase III development as a first-in-class treatment for Parkinson?s disease psychosis, and in Phase II development for Alzheimer?s disease psychosis; and has completed Phase II trial as a co-therapy for schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson?s disease and other neurological disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-2.61 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -85.71% Sales Growth - Q/Q-91.67% P/E-10.38
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-38.09% ROE-40.35% ROI
Current Ratio18.01 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin-123217% Net Profit Margin-122364% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.44 M Cash From Investing Activities38.47 M Cash From Operating Activities-25.35 M Gross Profit
Net Profit-40.38 M Operating Profit-40.55 M Total Assets301.96 M Total Current Assets299.9 M
Total Current Liabilities16.65 M Total Debt Total Liabilities16.87 M Total Revenue
Technical Data
High 52 week39.14 Low 52 week15.12 Last close17.87 Last change1.53%
RSI52.92 Average true range0.66 Beta1.75 Volume3.38 M
Simple moving average 20 days0.08% Simple moving average 50 days-2.47% Simple moving average 200 days-35.73%
Performance Data
Performance Week2.47% Performance Month-2.14% Performance Quart-30.98% Performance Half-40.61%
Performance Year-34.78% Performance Year-to-date-40.65% Volatility daily1.95% Volatility weekly4.36%
Volatility monthly8.94% Volatility yearly30.98% Relative Volume1230.89% Average Volume2.95 M
New High New Low


2019-09-17 23:00:00 | ACADIA Pharmaceuticals Prices Public Offering of Common Stock

2019-09-17 16:02:00 | ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

2019-09-17 15:25:42 | 5 Top Stock Trades for Wednesday: BA, ACB, PINS

2019-09-11 10:23:43 | 3 Hot Biotechs with High Upside Potential

2019-09-10 13:20:40 | 'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis

2019-09-10 11:41:03 | ACADIA Surges on Early Success of Nuplazid Dementia Study

2019-09-10 10:59:02 | Will ACADIA Continue to Surge Higher?

2019-09-10 08:39:00 | Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now?

2019-09-10 07:36:12 | The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris

2019-09-09 17:38:00 | Why Acadia Pharmaceuticals Stock Skyrocketed Today

2019-09-09 16:55:24 | ACADIA Pharmaceuticals Help Lift Biotech ETFs

2019-09-09 16:26:30 | Why This Biotech Stock Just Rocketed 63% After Hitting A 4-Year High

2019-09-09 16:13:00 | What Happened in the Stock Market Today

2019-09-09 14:33:33 | Acadia Stops Nuplazid Study Early After Drug Shows 'Statistically Superior Efficacy' In Dementia-Related Psychosis

2019-09-09 12:17:30 | A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019

2019-09-09 10:26:18 | Options Hot as ACADIA Pharmaceuticals Stock Soars

2019-09-09 09:05:01 | ACADIA Enters Oversold Territory

2019-09-09 07:31:00 | [video]Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment

2019-09-09 07:26:00 | Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint

2019-09-09 06:30:00 | ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis

2019-09-04 09:00:00 | ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019

2019-08-29 12:47:04 | Top Ranked Momentum Stocks to Buy for August 29th

2019-08-27 10:29:04 | Is There An Opportunity With ACADIA Pharmaceuticals Inc.'s NASDAQ:ACAD 37% Undervaluation?

2019-08-26 08:39:12 | Top Ranked Momentum Stocks to Buy for August 26th

2019-08-23 11:44:03 | Top Ranked Momentum Stocks to Buy for August 23rd

2019-08-20 08:34:12 | Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment

2019-08-16 10:42:02 | Palatin's PTN to Report Q4 Earnings: What's in the Cards?

2019-08-15 09:43:01 | Top Ranked Momentum Stocks to Buy for August 15th

2019-08-14 11:09:03 | Top Ranked Momentum Stocks to Buy for August 14th

2019-08-12 09:09:01 | Top Ranked Momentum Stocks to Buy for August 12th

2019-08-06 08:08:12 | ACADIA Pharmaceuticals Inc. ACAD Shares March Higher, Can It Continue?

2019-08-02 11:28:09 | Edited Transcript of ACAD earnings conference call or presentation 31-Jul-19 8:30pm GMT

2019-08-01 12:06:06 | Why Acadia Pharmaceuticals Stock Is Crushing It Today

2019-08-01 06:00:00 | Acadia Pharmaceuticals Beats Expectations in Q2

2019-08-01 02:24:23 | Acadia Pharmaceuticals ACAD Q2 2019 Earnings Call Transcript

2019-07-31 18:55:10 | Acadia Pharmaceuticals ACAD Reports Q2 Loss, Tops Revenue Estimates

2019-07-31 16:05:00 | ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results

2019-07-31 14:30:00 | ACADIA Pharmaceuticals, Inc. to Host Earnings Call

2019-07-31 07:06:00 | The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

2019-07-24 10:32:02 | Will Acadia Pharmaceuticals ACAD Report Negative Earnings Next Week? What You Should Know

2019-07-23 11:38:00 | Why Acadia Pharmaceuticals Is Tanking Today

2019-07-23 11:00:00 | Are These 2 Beaten-Down Biotech Stocks Worth Buying?

2019-07-23 07:36:34 | Why Is Acadia Pharmaceuticals Falling Today?

2019-07-23 07:26:32 | The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

2019-07-22 16:53:00 | Acadia stock drops as schizophrenia drug doesn't pass clinical trial

2019-07-22 16:44:49 | Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16%

2019-07-22 16:14:45 | Acadia's schizophrenia treatment fails to meet main goal of late-stage study

2019-07-22 16:05:00 | ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia

2019-07-22 13:56:00 | Acadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails Study

2019-07-17 09:00:00 | ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019